Jacob Golenser - Infectious Diseases

Author Information

Jacob Golenser is affiliated with the Department of Microbiology and Molecular Genetics at The Kuvin Centre for the Study of Infectious and Tropical Diseases, which is part of The Hebrew University of Jerusalem located in Ein Kerem, Jerusalem, Israel. His research primarily focuses on infectious diseases, with a notable emphasis on malaria treatment and drug delivery systems.

Research Contributions

Jacob Golenser has made significant contributions to the field of infectious diseases, particularly in the development and evaluation of treatment strategies for malaria. His work includes the encapsulation of antimalarial drugs such as Artemisone in various delivery systems, including poly(lactide-co-glycolide) micro- and nanoparticles, and innovative drug release mechanisms. Golenser's research aims to improve the efficacy and delivery of antimalarial drugs, explore different administration routes, and address formulation challenges to enhance treatment outcomes for diseases like cerebral malaria and schistosomiasis.

Aliases

Jacob Golenser is also known by several aliases, including J Golenser and J. Golenser. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	3539
H-index	34
Total Paper Count	141

Publications:

Meeting the Needs of a Potent Carrier for Malaria Treatment: Encapsulation of Artemisone in Poly(lactide‐ co ‐glycolide) Micro‐ and Nanoparticles

DOI: 10.1002/ppsc.202100152

Year: 2022

Efficient Treatment of Experimental Cerebral Malaria by an Artemisone-SMEDDS System: Impact of Application Route and Dosing Frequency

DOI: 10.1128/AAC.02106-20

Year: 2021

Transdermal delivery of artemisinins for treatment of pre-clinical cerebral malaria

DOI: 10.1016/j.ijpddr.2021.05.008

Year: 2021

Controlled and manageable release of antimalarial Artemisone by encapsulation in biodegradable carriers

DOI: 10.1016/j.eurpolymj.2020.109625

Year: 2020

Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy

DOI: 10.3390/pharmaceutics12060509

Year: 2020

Treatment of Experimental Cerebral Malaria by Slow Release of Artemisone From Injectable Pasty Formulation

DOI: 10.3389/fphar.2020.00846

Year: 2020

Asymmetric trisalkylamine cyclopropenium derivatives with antimicrobial activity.

DOI: 10.1016/j.bioorg.2020.104069

Year: 2020

Cyclopropenium-Based Biodegradable Polymers

DOI: 10.1021/ACS.MACROMOL.9B00430

Year: 2019

Unlocking Nanocarriers for the Programmed Release of Antimalarial Drugs

DOI: 10.1002/gch2.201600011

Year: 2017

Controlled release of artemisone for the treatment of experimental cerebral malaria

DOI: 10.1186/s13071-017-2018-7

Year: 2017

What Infectious Diseases Can Condoms Help Prevent?

Are There Diagnostic Implications?

What Technologies Are Used in Proteomics?

How Effective Are Masks?

What Challenges Does HTS Face?

What are Antimicrobials?

How is RT-PCR different from other diagnostic methods?

What are the global statistics?

What Other Diseases Do Anopheles Mosquitoes Transmit?

What role does environmental cleanliness play?

Partnered Content Networks

Relevant Topics